LivaNova (NASDAQ:LIVN) Releases FY24 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $3.10-$3.20 for the period, compared to the consensus EPS estimate of $3.09. LivaNova also updated its FY 2024 guidance to 3.100-3.200 EPS.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded down $1.34 during trading hours on Friday, hitting $46.98. The stock had a trading volume of 640,296 shares, compared to its average volume of 864,361. The stock’s fifty day simple moving average is $54.01 and its 200 day simple moving average is $54.39. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -78.30 and a beta of 0.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.71 and a current ratio of 3.45.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The business had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. During the same quarter last year, the business earned $0.43 earnings per share. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. Sell-side analysts anticipate that LivaNova will post 2.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on LIVN shares. Needham & Company LLC raised their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a buy rating in a research note on Wednesday. Robert W. Baird decreased their price objective on shares of LivaNova from $57.00 to $55.00 and set a neutral rating for the company in a research note on Thursday. StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a research note on Thursday, April 25th. Stifel Nicolaus raised their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock a buy rating in a research note on Thursday, July 25th. Finally, Mizuho raised their price objective on shares of LivaNova from $75.00 to $80.00 and gave the stock a buy rating in a research note on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $65.83.

Insider Buying and Selling

In related news, Director Daniel Jeffrey Moore sold 56,623 shares of LivaNova stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $60.11, for a total value of $3,403,608.53. Following the transaction, the director now owns 27,534 shares in the company, valued at approximately $1,655,068.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.